Global Mesothelioma Treatment Market, By Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Mesothelioma Treatment Market Analysis and Size
The global mesothelioma treatment market is expected to witness significant growth during the forecast period. Multiple treatment landscape and increase in research collaboration between the companies and institution as well as granting special designation by the regulatory authority are considered as positive indicator for the growth of this market. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of eosinophil driven diseases market. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global mesothelioma treatment market in the forecast period 2022-2029. The expected CAGR of global mesothelioma treatment market is tend to be around 9.0% in the mentioned forecast period. The market was valued at USD 240 million in 2021, and it would grow upto USD 478.22 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Mesothelioma is a type of malignant cancer in which abnormal growth of cells originates from the tissues that lines the internal organs such as lungs, stomach, heart and other organs. It is majorly caused by exposure of asbestos fibres which get trapped in the lungs and abdomen, resulting in mesothelioma development. The patient usually experiences dyspnea, respiratory complication, and pleural effusion in mesothelioma.
Mesothelioma Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Chemotherapy, Targeted Therapy, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Merck KGaA (Germany), Novartis AG (Switzerland), Beckman Coulter Inc. (U.S.), bioMerieux (France), Bio-Rad Laboratories, Inc (U.S.), Danaher (U.S.), Hologic (U.S.), Gilead Sciences, Inc. (U.S.), Emcure Pharmaceuticals Limited. (India), Cipla Inc. (U.S.), Hetero (India), Bausch Health Companies Inc. (Canada), Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), AstraZeneca (U.K.), Sanofi S.A. (France), Arena Pharmaceuticals, Inc. (U.S.), ONO PHARMACEUTICAL CO., LTD (Japan)
|
|
Market Opportunities
|
|
Global Mesothelioma Treatment Market Dynamics
Drivers
- Increased Approval Gains for Efficient Combination Therapy
Most of the companies are focusing on gaining approvals for drugs that can treat this disease. There are very few companies that have patents for procedures, and there are some companies that are conducting clinical trials focusing on different combination drugs. For instance, Boehringer Ingelheim (B.I.) entered into phase 3 trial for its double-blind, randomized, phase 3 study of Nintedanib in combination with Pemetrexed or Cisplatin followed by the continuation of Nintedanib monotherapy versus placebo in combination with Pemetrexed / Cisplatin followed by continuing placebo monotherapy for mesothelioma treatment.
- High Prevalence of Mesothelioma
As per the reports of the Cancer Research U.K., 1 in every 710 women and 1 in every 140 men are diagnosed with malignant mesothelioma. It has been observed that there is a rising trend of malignant mesothelioma cases in men. This boosts the market growth.
Opportunities
- Increased Exposure To Increased Pollution
People, especially mine workers are at a higher risk of developing mesothelioma due to asbestos (industrial pollutant). The chances of mesothelioma are increased in polluted areas by 2 to 10 fold compared to non-polluted areas. In addition, people exposed to a high dose of radiation, namely zeolites, are at risk of developing malignant mesothelioma.
- Increasing Demand for Retail Pharmacies
The rise in the number of drugs for mesothelioma delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Low Surveillance Rate
The 5-year mesothelioma survival rate for pleural mesothelioma is nearly 10%. Patients suffering from peritoneal mesothelioma have a 65% 5-year survival rate. According to the data from the May 2022 study, the annual number of malignant mesothelioma deaths amplified to 25%, from 489 in 1999 to 614 in 2020, and the yearly age-adjusted death rate for women reduced from 4.83 per 1 million in 1999 to 4.15 in 2020.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global mesothelioma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global mesothelioma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In October 2020: FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. The Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab for the better improvement of the patients.
Global Mesothelioma Treatment Market Scope
The global mesothelioma treatment market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Chemotherapy
- Targeted Therapy
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Mesothelioma Treatment Market Regional Analysis/Insights
The global mesothelioma treatment market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global mesothelioma treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global mesothelioma treatment market throughout the forecasted period due to the government funding and awareness.
North America dominates the market due to the increase prevalence of mesothelioma and large availability of treatment options for patient suffering of mesothelioma.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Mesothelioma Treatment Market Share Analysis
The global mesothelioma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global mesothelioma treatment market.
Key players operating in the global mesothelioma treatment market include:
- Merck KGaA (Germany)
- Novartis AG (Switzerland)
- Beckman Coulter Inc. (U.S.)
- bioMerieux (France)
- Bio-Rad Laboratories, Inc (U.S.)
- Danaher (U.S.)
- Hologic (U.S.)
- Gilead Sciences, Inc. (U.S.)
- Emcure Pharmaceuticals Limited. (India)
- Cipla Inc. (U.S.)
- Hetero (India)
- Bausch Health Companies Inc. (Canada)
- Johnson & Johnson Private Limited (U.S.)
- Mylan N.V. (U.S.)
- Sun Pharmaceutical Industries Limited (India)
- AstraZeneca (U.K.)
- Sanofi S.A. (France)
- Arena Pharmaceuticals, Inc. (U.S.)
- ONO PHARMACEUTICAL CO., LTD (Japan)
SKU-